Via practica 6/2013
Current recommendations for the treatment of growth factors granulocytopoiesis
There is vast spectrum of chemotherapeutic regimens we are able to administer patients with malignant tumors, but the efectivity of chemotherapy is limited by toxicity of cytostatic agents. One of the most limiting factors in systemic treatment is myelotoxicity, which can unfavourably influence treatment course with treatment delays, dose reductions and possibly compromise treatment outcome. This article will discuss treatment with granulocytopoiesis colony stimulating factors (filgrastim, pegfilgrastim), latest recommendations for administration and their impact on present oncological treatment.
Keywords: myelotoxicity, febrile neutropenia, G-CSF, filgrastim, pegfilgrastim.
